Summary of Conference Call for Yuan Dong Bio (苑东生物) Company Overview - **Company**: Yuan Dong Bio (苑东生物) - **Industry**: Pharmaceutical, focusing on drug development and research Key Points R&D Performance and Future Outlook - Yuan Dong invests 20% of its revenue annually in R&D, ranking among the top in the A-share market [3] - The company is transitioning from high-end generic drugs to more competitive controlled narcotics, achieving significant results [3] - Two Class II controlled narcotics, Nabuphine and Butorphanol, are expected to be approved in 2024, with sales projected to grow from 60 million RMB in 2025 to over 200 million RMB by 2026 [3][4] - The company faces challenges in the non-controlled antagonist product segment due to centralized procurement impacts, and its efficiency in developing new Class I drugs is lagging behind competitors [3][5] Strategic Developments - The Shanghai Chaoyang platform enhances the company's capabilities in developing Class I new drugs, particularly the IKZF13 molecular glue for multiple myeloma, which has a significant market potential [6][7] - HP001, a new drug in clinical trials, shows promising results with an objective response rate (ORR) of 83.3% in high-dose groups, outperforming some combination therapies [10] Competitive Landscape - The company is monitoring competition from BeiGene and Nurix in the BTK ProTech product space, with HP002 aiming to replicate BeiGene's success [11] - VAVONE molecular glue HP003 is being developed to target autoimmune oral therapies, showing better efficacy than existing products [12] Future R&D Directions - The company plans to extend its R&D focus to the Dac platform, utilizing molecular glue as a payload, with promising preliminary data [13] - Key developments expected by 2026 include significant data from VIV1 molecular glue, BDK protect IND, and IKZF13 molecules [13] Financial Projections - The overall valuation of the company is projected to reach 25.5 billion RMB by 2026, with the main business valued at approximately 8 billion RMB [14] - Anticipated profits for 2025 are estimated between 270 million to 280 million RMB, with a growth rate of over 20% expected to continue [14][15] Additional Insights - The company has faced challenges in the past few years, particularly in the Class I new drug sector, with only one drug entering Phase I clinical trials in the last decade [5] - The focus on improving R&D efficiency and quality is expected to positively influence future operational trends [15]

Core Insights - China's innovative drug transaction value has surpassed that of the United States, indicating growing global recognition of domestic innovations [1][4] - The total transaction amount for outbound licensing of innovative drugs from China is projected to reach $135.655 billion by December 31, 2025, with a significant increase in both upfront payments and transaction numbers compared to 2024 [1][4] - The surge in outbound licensing reflects the international community's acknowledgment of the value of Chinese innovative drugs, driven by reforms in drug approval processes and supportive policies [1][4] Transaction Overview - In 2025, the total amount of outbound licensing transactions for innovative drugs from China exceeded $1,300 billion, with over 150 transactions, significantly surpassing the 2024 figures of $519 billion and 94 transactions [4][5] - The first transaction of 2025 involved Innovent Biologics partnering with Roche, receiving an upfront payment of $80 million and potential milestone payments of up to $1 billion [4] - Notable transactions include a record upfront payment of $1.25 billion from 3SBio to Pfizer for a global licensing agreement, and a total transaction amount exceeding $12 billion with GSK [5] Market Dynamics - The demand for Chinese innovative assets is expected to persist as multinational corporations (MNCs) face patent cliffs and cost-cutting pressures [8][9] - The global pharmaceutical supply chain is undergoing significant adjustments, with MNCs increasingly looking to China for early-stage innovative pipelines due to cost-effectiveness and potential superior outcomes [9][10] - The shift in business development (BD) models is evident, with a move towards co-development and co-commercialization agreements, allowing Chinese companies to play a more active role in global markets [10][11] Industry Trends - China's innovative drug pipeline accounts for approximately 30% of the global total, with significant achievements in key therapeutic areas such as PD-1/VEGF bispecific antibodies [8] - The industry is transitioning from a "fast-follower" to a "first-in-class" model, emphasizing the importance of clinical value and unmet medical needs [6][15] - The approval of 76 innovative drugs in 2025, with a high percentage being domestically developed, highlights the growing capabilities of Chinese pharmaceutical companies [5][6] Future Outlook - The innovative drug sector in China is expected to face challenges in maintaining the momentum of BD transactions, with concerns about sustainability and the potential for a slowdown in transaction values [14][15] - The focus for 2026 will likely shift towards solidifying clinical value and addressing unmet needs, particularly in oncology and autoimmune diseases [15][16] - The Chinese regulatory body plans to implement more measures to support the rapid development of innovative drugs, indicating a commitment to fostering industry growth [15][16]

Core Viewpoint - China's innovative drug transaction value has surpassed that of the United States, indicating that domestic innovations are gradually gaining recognition in the global mainstream market [1][2]. Group 1: Transaction Data and Growth - By December 31, 2025, the total transaction amount for China's innovative drug business development (BD) overseas reached $135.655 billion (approximately 948.3 billion RMB), with an upfront payment of $7 billion and a total of 157 transactions, significantly exceeding the 2024 figures of $51.9 billion and 94 transactions [1][2]. - The total amount of overseas licensing for innovative drugs in China for 2025 is 2.5 times that of 2024 and 3.2 times that of the U.S. during the same period [2]. - The first transaction of 2025 involved Innovent Biologics partnering with Roche, receiving an upfront payment of $80 million and potential milestone payments of up to $1 billion [2]. Group 2: Notable Collaborations - In May 2025, 3SBio set a record for upfront payments in China by securing a global licensing agreement with Pfizer for $1.25 billion upfront and a total transaction value of $6 billion [3]. - Other significant collaborations include Heng Rui Medicine's partnership with GSK exceeding $12 billion and Innovent's collaboration with Takeda potentially reaching $11.4 billion [3]. Group 3: Industry Trends and Future Outlook - The surge in BD transactions is attributed to multinational corporations (MNCs) facing a "patent cliff" and cost-cutting pressures, increasing their demand for Chinese innovative assets [6][10]. - China's innovative drug pipeline accounts for approximately 30% of the global total, positioning the country as a significant player in key therapeutic areas such as PD-1/VEGF bispecific antibodies [6]. - The industry is transitioning from a "fast-follower" to a "first-in-class" or "best-in-class" model, emphasizing lean research and precise financing [4][10]. Group 4: Market Dynamics and Challenges - The global pharmaceutical supply chain is undergoing deep adjustments, and the valuation system is being restructured, presenting challenges for China's BD transactions [10]. - The industry is expected to face execution risks and potential disputes, with a consensus that while the BD boom will continue, the scale of transactions may not sustain the same explosive growth seen in 2025 [10][12]. - The focus for 2026 will shift towards solidifying clinical value and addressing unmet clinical needs, particularly in oncology and autoimmune disease sectors [10][12].

Group 1 - As of January 4, 2026, a total of 105 companies listed on the Shanghai Stock Exchange have disclosed share repurchase and increase progress announcements, with 98 related to repurchases and 7 to increases [1] - The total repurchase limit disclosed by 70 companies on the main board exceeds 27.8 billion yuan, while 6 companies reported shareholder increases with a total limit exceeding 4 billion yuan [1] - Notable companies such as Kweichow Moutai, Haier Smart Home, and Sany Heavy Industry have reported repurchase amounts exceeding 4.8 billion yuan [1] Group 2 - China Merchants Industry Holdings has repurchased shares worth 8.25 billion yuan as of December 31, 2025, under a plan to repurchase between 749 million yuan and 1.498 billion yuan [2] - Haier Smart Home and Sany Heavy Industry have reported repurchase amounts of 1.08 billion yuan and 1.36 billion yuan, respectively [2] - Seven companies, including Dongfang Electric and Binhu Chemical, have disclosed increases totaling over 1.7 billion yuan, with significant contributions from stakeholders like the Three Gorges Group [2] Group 3 - In 2025, the total amount of new repurchase and increase plans by companies on the Shanghai Stock Exchange exceeded 138 billion yuan, reflecting a strong commitment to market confidence [3] - Kweichow Moutai completed a 6 billion yuan repurchase plan and initiated an additional plan of 1.5 billion to 3 billion yuan in November 2025 [3] - The Wind stock repurchase index rose by 31.31% in 2025, indicating a historical high and reflecting the positive impact of repurchase and increase actions on market sentiment [3]

Core Insights - In 2025, China's innovative drug BD transactions reached a record high, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, marking a significant milestone for the industry [1][14][17] Group 1: Transaction Highlights - December alone saw 15 overseas licensing deals with a potential total value exceeding $16 billion, concluding the year on a high note [1][14] - The trend of milestone payments is emerging, with several companies triggering these payments, indicating the strength of Chinese innovative drugs [4][19] - Notable milestone payments include $11 million from AstraZeneca for a joint therapy approval and $30 million from Instil for a clinical trial initiation [21][22] Group 2: Evolving Collaboration Models - The BD transaction landscape is diversifying, moving from "Newco" models to "Co-Co" (co-development and co-commercialization) partnerships, reflecting a shift in strategy among Chinese pharmaceutical companies [9][25] - A landmark deal between Innovent Biologics and Takeda, valued at $11.4 billion, exemplifies the "Co-Co" model, allowing shared development costs and profits [26][27] - The "Newco" model remains prevalent, with 9 such transactions recorded in 2025, showcasing the continued appeal of equity-linked collaborations [28] Group 3: Industry Implications - The increase in milestone payments not only alleviates cash flow pressures for companies but also signifies progress in global development efforts [5][19] - The successful execution of these transactions is expected to enhance global trust in Chinese innovative drugs, paving the way for more overseas collaborations [24] - The evolution of collaboration models indicates a growing confidence and negotiation power of Chinese pharmaceutical companies in the global market [10][27]

恒瑞医药（600276）(01276)发布公告，2025年12月，公司通过上海证券交易所交易系统以集中竞价交 易方式回购股份0股。截至2025年12月31日，公司本次股份回购方案累计通过上海证券交易所交易系统 以集中竞价交易方式回购股份889.87万股，已回购股份占公司总股本的比例为0.13%，购买的最高价为 人民币70.00元/股，最低价为人民币59.32元/股，已支付的总金额为人民币59,521.63万元(不含交易费 用)。 ...

Core Insights - Novo Nordisk won a favorable ruling from the Supreme People's Court of China regarding the core patent for semaglutide, which is significant for the company's operations in China and reflects the government's support for pharmaceutical innovation [1][2] - Despite the legal victory, Novo Nordisk faces challenges with the expiration of the semaglutide patent, which is set to expire in March 2026, potentially impacting global sales growth [2] Patent and Legal Developments - The patent dispute began in June 2021 when East China Pharmaceutical filed a request to invalidate the core patent for semaglutide, which was initially ruled invalid by the National Intellectual Property Administration in September 2022 [1] - The Supreme People's Court's ruling confirms the validity of the patent, concluding a legal battle that lasted over four years [2] Market Performance and Competition - Semaglutide generated $25.5 billion in revenue in the first three quarters of 2025, positioning it to become the top-selling drug in the global pharmaceutical industry [2] - In China, there are currently 10 domestic applications for semaglutide biosimilars under review, with several companies, including East China Pharmaceutical and Lijun Group, advancing their products through clinical trials [3] - The competitive landscape is intensifying with the emergence of biosimilars and other GLP-1 drugs, such as Eli Lilly's tirzepatide, which has been offered at significantly reduced prices [3]

海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-001 江苏恒瑞医药股份有限公司 关于回购公司 ...

Core Insights - China's innovative drug transaction value has surpassed that of the United States, indicating a growing global recognition of domestic innovations [1][3] - The total transaction amount for outbound licensing of innovative drugs from China is projected to reach $135.655 billion by December 31, 2025, with a significant increase in both upfront payments and transaction numbers compared to 2024 [1][3] - The surge in outbound licensing reflects the international community's acknowledgment of the value of Chinese innovative drugs, driven by a series of reforms and policies encouraging innovation [1][4] Transaction Overview - In 2025, the total amount of outbound licensing transactions for Chinese innovative drugs exceeded $1,300 billion, accounting for 49% of the global total, significantly surpassing the $519 billion recorded in 2024 [3][4] - The first transaction of 2025 involved Innovent Biologics partnering with Roche, which included an upfront payment of $80 million and potential milestone payments of up to $1 billion [3] - Notable transactions include a record upfront payment of $1.25 billion from 3SBio to Pfizer for a global licensing agreement, highlighting the increasing scale of these deals [3][4] Market Dynamics - The demand for Chinese innovative assets is expected to persist as multinational corporations (MNCs) face patent cliffs and cost-cutting pressures [7][8] - The global pharmaceutical supply chain is undergoing significant adjustments, with a shift in focus towards collaborative development and commercialization models, such as the Co-Co model [9][10] - Chinese companies are increasingly recognized for their capabilities in developing innovative therapies, moving from being fast followers to first-in-class innovators [6][7] Future Outlook - The Chinese innovative drug sector is anticipated to experience a critical sales growth phase starting in 2026, transitioning from a focus on research and development to performance realization [5][6] - The industry is expected to face challenges in maintaining the momentum of high-value transactions, with a potential shift in focus towards clinical value and unmet medical needs [12][14] - Regulatory support from the National Medical Products Administration (NMPA) is expected to enhance the development of innovative drugs, particularly those with new mechanisms and targets [14]

Group 1 - HuLuWa's chairman Liu Jingping is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The company assures that all production and operational activities are proceeding normally and will cooperate with the CSRC during the investigation [1] Group 2 - HengRui Medicine has signed an exclusive licensing agreement with Hansoh Pharmaceutical for the SHR6508 project, with an initial payment of 30 million RMB [2] - SHR6508 is a new calcium-sensing receptor modulator intended for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing dialysis, currently in phase III clinical trials [2] - HengRui is eligible for milestone payments up to 190 million RMB and a sales commission of up to 9% based on quarterly net sales [2] Group 3 - YueKang Pharmaceutical has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [3] - The application materials are subject to updates and revisions as per regulatory requirements [3] Group 4 - Novo Nordisk announced a favorable ruling from the Supreme People's Court of China regarding the patent for semaglutide, a key component in its obesity and diabetes medications [4] - The company anticipates a low single-digit negative impact on global sales growth in 2026 due to the expiration of the patent in some markets [4] Group 5 - Sinovac Biotech has secured an exclusive contract to supply over 8 million doses of flu vaccine to the Chilean government for the 2026 flu season [5][6] - The first batch of vaccines is expected to arrive in Chile by the end of January 2026, continuing Sinovac's role as the sole supplier for the second consecutive year [6] Group 6 - Carestream Health has completed a strategic restructuring, splitting into two independent companies, with its international business unit acquired by Midea Group [7] - The specific transaction amount for the asset sale has not been disclosed [7] Group 7 - Haiwang Bio plans to sell its pharmaceutical distribution subsidiary for 248.08 million RMB to focus on high-margin sectors like medical devices [8] - The divestment aims to optimize the company's asset and business structure, reduce operational costs, and enhance long-term strategic focus [8]